Intellia Therapeutics (NTLA) 44th Annual J.P. Morgan Healthcare Conference summary

Key clinical and pipeline updates

• Three phase 3 trials are ongoing, with over 600 patients dosed and a robust safety database accumulated.

• Lombozi for hereditary angioedema (HAE) completed phase 3 enrollment, exceeding targets due to high patient interest.

• Nexi for transthyretin amyloidosis (TTR) is in phase 3 but currently on clinical hold; over 650 patients enrolled before the hold.

• Lombozi demonstrated 76% of patients attack-free and prophylaxis-free at 12 months in pooled phase 1/2 analysis.

• Nexi showed rapid, deep, and durable TTR reduction, with a 70% reduction in mortality over three years in matched analysis.

Market opportunity and commercialization plans

• HAE market expected to double to $6 billion by decade's end; TTR market projected to exceed $16 billion.

• Lombozi is positioned as a potential functional cure, offering freedom from attacks and ongoing therapy.

• Commercial launch of Lombozi targeted for first half of 2027, with BLA submission planned for the second half of this year.

• U.S. commercialization is the initial focus, with international expansion under consideration, potentially via partnership.

• Payers recognize the value of a one-time therapy, given current high costs and resource demands of existing treatments.

Regulatory and safety updates

• Lombozi phase 3 uses the commercial form of the product, with CMC work completed and favorable regulatory designations.

• Nexi's clinical hold was triggered by a patient death due to sepsis from a perforated ulcer, not liver failure.

• Incidence of grade 4 transaminase elevations in Nexi phase 3 is less than 1%.

• Active engagement with the FDA is ongoing to resolve the clinical hold, with historical holds typically lasting 3–9 months.

• Investigators and sites remain engaged, and enrollment is expected to resume strongly once the hold is lifted.